John E Brazier

List of Publications by Citations

Source: https://exaly.com/author-pdf/1746782/john-e-brazier-publications-by-citations.pdf

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

287
papers

20,362
citations

h-index

313
ext. papers

23,030
ext. citations

3 7.01
ext. papers

23,030
ext. citations

23,030
ext. citations

#	Paper	IF	Citations
287	The estimation of a preference-based measure of health from the SF-36. <i>Journal of Health Economics</i> , 2002 , 21, 271-92	3.5	2124
286	Cross-validation of item selection and scoring for the SF-12 Health Survey in nine countries: results from the IQOLA Project. International Quality of Life Assessment. <i>Journal of Clinical Epidemiology</i> , 1998 , 51, 1171-8	5.7	1991
285	Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. <i>Quality of Life Research</i> , 2005 , 14, 1523-32	3.7	952
284	The estimation of a preference-based measure of health from the SF-12. <i>Medical Care</i> , 2004 , 42, 851-9	3.1	939
283	A comparison of the EQ-5D and SF-6D across seven patient groups. <i>Health Economics (United Kingdom)</i> , 2004 , 13, 873-84	2.4	584
282	The factor structure of the SF-36 Health Survey in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. <i>Journal of Clinical Epidemiology</i> , 1998 , 51, 1159-65	5.7	507
281	Deriving a preference-based single index from the UK SF-36 Health Survey. <i>Journal of Clinical Epidemiology</i> , 1998 , 51, 1115-28	5.7	501
280	Health, Health-Related Quality of Life, and Quality of Life: What is the Difference?. <i>Pharmacoeconomics</i> , 2016 , 34, 645-9	4.4	477
279	The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries: results from the IQOLA Project. International Quality of Life Assessment. <i>Journal of Clinical Epidemiology</i> , 1998 , 51, 1167-70	5.7	449
278	A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. <i>European Journal of Health Economics</i> , 2010 , 11, 215-25	3.6	324
277	Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra. <i>Health Economics (United Kingdom)</i> , 2005 , 14, 339-47	2.4	313
276	Tests of data quality, scaling assumptions, and reliability of the SF-36 in eleven countries: results from the IQOLA Project. International Quality of Life Assessment. <i>Journal of Clinical Epidemiology</i> , 1998 , 51, 1149-58	5.7	310
275	What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. <i>Health and Quality of Life Outcomes</i> , 2003 , 1, 4	3	306
274	A comparison of generic, indirect utility measures (the HUI2, HUI3, SF-6D, and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. <i>Social Science and Medicine</i> , 2005 , 60, 1571-82	5.1	301
273	Evaluating translations of health status questionnaires. Methods from the IQOLA project. International Quality of Life Assessment. <i>International Journal of Technology Assessment in Health Care</i> , 1995 , 11, 525-51	1.8	256
272	Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. <i>Health Technology Assessment</i> , 2014 , 18, 1-224	4.4	207
271	Use of structural equation modeling to test the construct validity of the SF-36 Health Survey in ten countries: results from the IQOLA Project. International Quality of Life Assessment. <i>Journal of Clinical Epidemiology</i> , 1998 , 51, 1179-88	5.7	181

270	Populating an economic model with health state utility values: moving toward better practice. <i>Value in Health</i> , 2010 , 13, 509-18	3.3	163
269	Modelling SF-6D health state preference data using a nonparametric Bayesian method. <i>Journal of Health Economics</i> , 2007 , 26, 597-612	3.5	158
268	Using a discrete choice experiment to estimate health state utility values. <i>Journal of Health Economics</i> , 2012 , 31, 306-18	3.5	154
267	Valuing health-related quality of life. A review of health state valuation techniques. <i>Pharmacoeconomics</i> , 2000 , 17, 151-65	4.4	146
266	Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study. <i>Journal of Bone and Mineral Research</i> , 2007 , 22, 135-41	6.3	143
265	Health-related quality of life and cost impact of irritable bowel syndrome in a UK primary care setting. <i>Pharmacoeconomics</i> , 2002 , 20, 455-62	4.4	143
264	A systematic review, psychometric analysis and qualitative assessment of generic preference-based measures of health in mental health populations and the estimation of mapping functions from widely used specific measures. <i>Health Technology Assessment</i> , 2014 , 18, vii-viii, xiii-xxv, 1-188	4.4	141
263	Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). <i>Value in Health</i> , 2008 , 11, 1131-43	3.3	133
262	Comparison of Rasch and summated rating scales constructed from SF-36 physical functioning items in seven countries: results from the IQOLA Project. International Quality of Life Assessment. <i>Journal of Clinical Epidemiology</i> , 1998 , 51, 1203-14	5.7	130
261	Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies. <i>PLoS ONE</i> , 2012 , 7, e31115	3.7	130
260	A checklist for judging preference-based measures of health related quality of life: learning from psychometrics. <i>Health Economics (United Kingdom)</i> , 1999 , 8, 41-51	2.4	125
259	Mapping SF-36 onto the EQ-5D index: how reliable is the relationship?. <i>Health and Quality of Life Outcomes</i> , 2009 , 7, 27	3	122
258	Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence. <i>Journal of Health Services Research and Policy</i> , 2007 , 12, 56-8	2.4	122
257	Deriving a preference-based measure for cancer using the EORTC QLQ-C30. <i>Value in Health</i> , 2011 , 14, 721-31	3.3	119
256	Quality of life of people with mental health problems: a synthesis of qualitative research. <i>Health and Quality of Life Outcomes</i> , 2012 , 10, 138	3	115
255	Should patients have a greater role in valuing health states?. <i>Applied Health Economics and Health Policy</i> , 2005 , 4, 201-8	3.4	114
254	The impact of age-related macular degeneration on health status utility values. <i>Investigative Ophthalmology and Visual Science</i> , 2005 , 46, 4016-23		112
253	A review of the use of health status measures in economic evaluation. <i>Journal of Health Services Research and Policy</i> , 1999 , 4, 174-84	2.4	108

252	A comparison of four indirect methods of assessing utility values in rheumatoid arthritis. <i>Medical Care</i> , 2004 , 42, 1125-31	3.1	103
251	Using rank data to estimate health state utility models. <i>Journal of Health Economics</i> , 2006 , 25, 418-31	3.5	99
250	Estimation of a preference-based index from a condition-specific measure: the King's Health Questionnaire. <i>Medical Decision Making</i> , 2008 , 28, 113-26	2.5	96
249	Valuation of the SF-6D Health States Is Feasible, Acceptable, Reliable, and Valid in a Chinese Population. <i>Value in Health</i> , 2008 , 11, 295-303	3.3	93
248	A review of generic preference-based measures of health-related quality of life in visual disorders. <i>Value in Health</i> , 2012 , 15, 118-27	3.3	91
247	Is the EQ-5D fit for purpose in mental health?. British Journal of Psychiatry, 2010, 197, 348-9	5.4	91
246	Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. <i>Medical Decision Making</i> , 2002 , 22, 27-38	2.5	91
245	Health-state utility values in breast cancer. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010 , 10, 553-66	2.2	90
244	Valuing Child Health Utility 9D health states with a young adolescent sample: a feasibility study to compare best-worst scaling discrete-choice experiment, standard gamble and time trade-off methods. <i>Applied Health Economics and Health Policy</i> , 2011 , 9, 15-27	3.4	90
243	The facilitators and barriers to implementing patient reported outcome measures in organisations delivering health related services: a systematic review of reviews. <i>Journal of Patient-Reported Outcomes</i> , 2018 , 2, 46	2.6	89
242	Measuring quality of life in mental health: are we asking the right questions?. <i>Social Science and Medicine</i> , 2014 , 120, 12-20	5.1	87
241	An investigation of the construct validity of the ICECAP-A capability measure. <i>Quality of Life Research</i> , 2013 , 22, 1831-40	3.7	84
240	How valid and responsive are generic health status measures, such as EQ-5D and SF-36, in schizophrenia? A systematic review. <i>Value in Health</i> , 2011 , 14, 907-20	3.3	84
239	An Australian discrete choice experiment to value eq-5d health states. <i>Health Economics (United Kingdom)</i> , 2014 , 23, 729-42	2.4	82
238	Testing the equivalence of translations of widely used response choice labels: results from the IQOLA Project. International Quality of Life Assessment. <i>Journal of Clinical Epidemiology</i> , 1998 , 51, 933	-4 ⁵ 4 ⁷	80
237	Measuring and Valuing Health Benefits for Economic Evaluation 2016,		79
236	Discriminative capacity of the EQ-5D, SF-6D, and SF-12 as measures of health status in population health survey. <i>Quality of Life Research</i> , 2010 , 19, 853-64	3.7	78
235	Recovering Quality of Life (ReQoL): a new generic self-reported outcome measure for use with people experiencing mental health difficulties. <i>British Journal of Psychiatry</i> , 2018 , 212, 42-49	5.4	77

234	Valuing SF-6D Health States Using a Discrete Choice Experiment. <i>Medical Decision Making</i> , 2014 , 34, 77	3-286	76
233	Cost effectiveness of a community based exercise programme in over 65 year olds: cluster randomised trial. <i>Journal of Epidemiology and Community Health</i> , 2004 , 58, 1004-10	5.1	76
232	An assessment of the construct validity of the ASCOT measure of social care-related quality of life with older people. <i>Health and Quality of Life Outcomes</i> , 2012 , 10, 21	3	75
231	Developing adolescent-specific health state values for economic evaluation: an application of profile case best-worst scaling to the Child Health Utility 9D. <i>Pharmacoeconomics</i> , 2012 , 30, 713-27	4.4	74
230	A view from the bridge: agreement between the SF-6D utility algorithm and the Health Utilities Index. <i>Health Economics (United Kingdom)</i> , 2003 , 12, 975-81	2.4	74
229	Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D. <i>British Journal of Psychiatry</i> , 2014 , 205, 236-43	5.4	73
228	An assessment of the construct validity of the CHU9D in the Australian adolescent general population. <i>Quality of Life Research</i> , 2012 , 21, 717-25	3.7	71
227	Discounting and cost-effectiveness in NICE - stepping back to sort out a confusion. <i>Health Economics</i> (United Kingdom), 2006 , 15, 1-4	2.4	71
226	Are indirect utility measures reliable and responsive in rheumatoid arthritis patients?. <i>Quality of Life Research</i> , 2005 , 14, 1333-44	3.7	69
225	Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. <i>Value in Health</i> , 2011 , 14, 539-45	3.3	68
224	Valuing health States for use in cost-effectiveness analysis. <i>Pharmacoeconomics</i> , 2008 , 26, 769-79	4.4	66
223	Estimating preference-based single index measures for dementia using DEMQOL and DEMQOL-Proxy. <i>Value in Health</i> , 2012 , 15, 346-56	3.3	65
222	Using the health assessment questionnaire to estimate preference-based single indices in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2007 , 57, 963-71		63
221	Tailored psychotherapy for patients with functional neurological symptoms: a pilot study. <i>Journal of Psychosomatic Research</i> , 2007 , 63, 625-32	4.1	62
220	Estimating a preference-based index for a 5-dimensional health state classification for asthma derived from the asthma quality of life questionnaire. <i>Medical Decision Making</i> , 2011 , 31, 281-91	2.5	61
219	Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report. <i>Value in Health</i> , 2019 , 22, 267-275	3.3	60
218	The first stage of developing preference-based measures: constructing a health-state classification using Rasch analysis. <i>Quality of Life Research</i> , 2009 , 18, 253-65	3.7	60
217	Estimating a preference-based single index from the Overactive Bladder Questionnaire. <i>Value in Health</i> , 2009 , 12, 159-66	3.3	60

216	Valuing the Child Health Utility 9D: Using profile case best worst scaling methods to develop a new adolescent specific scoring algorithm. <i>Social Science and Medicine</i> , 2016 , 157, 48-59	5.1	60
215	A comparison of methods for converting DCE values onto the full health-dead QALY scale. <i>Medical Decision Making</i> , 2015 , 35, 328-40	2.5	59
214	An exploratory study to test the impact on three "bolt-on" items to the EQ-5D. <i>Value in Health</i> , 2015 , 18, 52-60	3.3	58
213	Predicting the short form-6D preference-based index using the eight mean short form-36 health dimension scores: estimating preference-based health-related utilities when patient level data are not available. <i>Value in Health</i> , 2009 , 12, 346-53	3.3	58
212	The validity of generic and condition-specific preference-based instruments: the ability to discriminate asthma control status. <i>Quality of Life Research</i> , 2008 , 17, 453-62	3.7	58
211	Health state values for the HUI 2 descriptive system: results from a UK survey. <i>Health Economics</i> (United Kingdom), 2005 , 14, 231-44	2.4	58
210	The importance of content and face validity in instrument development: lessons learnt from service users when developing the Recovering Quality of Life measure (ReQoL). <i>Quality of Life Research</i> , 2018 , 27, 1893-1902	3.7	57
209	Estimating a preference-based index from the Japanese SF-36. <i>Journal of Clinical Epidemiology</i> , 2009 , 62, 1323-31	5.7	57
208	The impact of ADHD on the health and well-being of ADHD children and their siblings. <i>European Child and Adolescent Psychiatry</i> , 2016 , 25, 1217-1231	5.5	57
207	Mapping onto Eq-5 D for patients in poor health. <i>Health and Quality of Life Outcomes</i> , 2010 , 8, 141	3	56
206	Comparison of valuation methods used to generate the EQ-5D and the SF-6D value sets. <i>Journal of Health Economics</i> , 2006 , 25, 334-46	3.5	54
205	Using DCE and ranking data to estimate cardinal values for health states for deriving a preference-based single index from the sexual quality of life questionnaire. <i>Health Economics</i> (United Kingdom), 2009 , 18, 1261-76	2.4	53
204	The use of rasch analysis in reducing a large condition-specific instrument for preference valuation: the case of moving from AQLQ to AQL-5D. <i>Medical Decision Making</i> , 2011 , 31, 195-210	2.5	52
203	The development of a QALY measure for epilepsy: NEWQOL-6D. <i>Epilepsy and Behavior</i> , 2012 , 24, 36-43	3.2	51
202	The role of patient preferences in cost-effectiveness analysis: a conflict of values?. <i>Pharmacoeconomics</i> , 2009 , 27, 705-12	4.4	51
201	Binary choice health state valuation and mode of administration: head-to-head comparison of online and CAPI. <i>Value in Health</i> , 2013 , 16, 104-13	3.3	50
200	US valuation of the SF-6D. Medical Decision Making, 2013, 33, 793-803	2.5	50
199	Estimating a preference-based single index for the Impact of Weight on Quality of Life-Lite (IWQOL-Lite) instrument from the SF-6D. <i>Value in Health</i> , 2004 , 7, 490-8	3.3	48

(2016-2015)

198	EQ-5D in skin conditions: an assessment of validity and responsiveness. <i>European Journal of Health Economics</i> , 2015 , 16, 927-39	3.6	46	
197	Estimating the SF-6D value set for a population-based sample of Brazilians. <i>Value in Health</i> , 2011 , 14, S108-14	3.3	46	
196	Comparison of the HUI3 with the SF-36 preference based SF-6D in a clinical trial setting. <i>Value in Health</i> , 2004 , 7, 602-9	3.3	46	
195	Examining the impact of 11 long-standing health conditions on health-related quality of life using the EQ-5D in a general population sample. <i>European Journal of Health Economics</i> , 2015 , 16, 141-51	3.6	45	
194	Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30. <i>Pharmacoeconomics</i> , 2018 , 36, 225-238	4.4	45	
193	Valuing condition-specific health states using simulation contact lenses. <i>Value in Health</i> , 2009 , 12, 793-9	93.3	45	
192	A Review of Generic Preference-Based Measures for Use in Cost-Effectiveness Models. <i>Pharmacoeconomics</i> , 2017 , 35, 21-31	4.4	44	
191	A preference-based measure of health: the VR-6D derived from the veterans RAND 12-Item Health Survey. <i>Quality of Life Research</i> , 2011 , 20, 1337-47	3.7	44	
190	Preparatory study for the revaluation of the EQ-5D tariff: methodology report. <i>Health Technology Assessment</i> , 2014 , 18, vii-xxvi, 1-191	4.4	44	
189	Assessing the Health-Related Quality of Life of Australian Adolescents: An Empirical Comparison of the Child Health Utility 9D and EQ-5D-Y Instruments. <i>Value in Health</i> , 2015 , 18, 432-8	3.3	43	
188	Improving Cross-Sector Comparisons: Going Beyond the Health-Related QALY. <i>Applied Health Economics and Health Policy</i> , 2015 , 13, 557-65	3.4	43	
187	Effect of adding a sleep dimension to the EQ-5D descriptive system: a "bolt-on" experiment. <i>Medical Decision Making</i> , 2014 , 34, 42-53	2.5	43	
186	Cost effectiveness of using cognitive screening tests for detecting dementia and mild cognitive impairment in primary care. <i>International Journal of Geriatric Psychiatry</i> , 2017 , 32, 1392-1400	3.9	42	
185	Cost-effectiveness of an improving access to psychological therapies service. <i>British Journal of Psychiatry</i> , 2013 , 202, 220-7	5.4	41	
184	The use of condition specific outcome measures in economic appraisal. <i>Health Economics (United Kingdom)</i> , 1995 , 4, 255-64	2.4	41	
183	Health and healthcare costs and benefits of exercise. <i>Pharmacoeconomics</i> , 1994 , 5, 109-22	4.4	41	
182	Using Rasch analysis to form plausible health states amenable to valuation: the development of CORE-6D from a measure of common mental health problems (CORE-OM). <i>Quality of Life Research</i> , 2011 , 20, 321-33	3.7	40	
181	Nothing About Us Without Us? A Comparison of Adolescent and Adult Health-State Values for the Child Health Utility-9D Using Profile Case Best-Worst Scaling. <i>Health Economics (United Kingdom)</i> , 2016 , 25, 486-96	2.4	40	

180	The Role of Condition-Specific Preference-Based Measures in Health Technology Assessment. <i>Pharmacoeconomics</i> , 2017 , 35, 33-41	4.4	39
179	A comparison of patient and general population weightings of EQ-5D dimensions. <i>Health Economics</i> (United Kingdom), 2009 , 18, 363-72	2.4	39
178	Mapping between Visual Analogue Scale and Standard Gamble data; results from the UK Health Utilities Index 2 valuation survey. <i>Health Economics (United Kingdom)</i> , 2006 , 15, 527-33	2.4	39
177	A comparison of the costs and performance of an emergency helicopter and land ambulances in a rural area. <i>Injury</i> , 1994 , 25, 145-53	2.5	39
176	Eliciting Societal Preferences for Weighting QALYs for Burden of Illness and End of Life. <i>Medical Decision Making</i> , 2016 , 36, 210-22	2.5	38
175	Systematic searching and selection of health state utility values from the literature. <i>Value in Health</i> , 2013 , 16, 686-95	3.3	38
174	Development and validation of a preference based measure derived from the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) for use in cost utility analyses. <i>Health and Quality of Life Outcomes</i> , 2008 , 6, 65	3	38
173	Valuing the EQ-5D and the SF-6D health states using subjective well-being: a secondary analysis of patient data. <i>Social Science and Medicine</i> , 2013 , 77, 97-105	5.1	37
172	Measuring and valuing mental health for use in economic evaluation. <i>Journal of Health Services Research and Policy</i> , 2008 , 13 Suppl 3, 70-5	2.4	37
171	Quality of life impact of mental health conditions in England: results from the adult psychiatric morbidity surveys. <i>Health and Quality of Life Outcomes</i> , 2014 , 12, 6	3	36
170	Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer. <i>Value in Health</i> , 2012 , 15, 1059-68	3.3	36
169	Whose values in health? An empirical comparison of the application of adolescent and adult values for the CHU-9D and AQOL-6D in the Australian adolescent general population. <i>Value in Health</i> , 2012 , 15, 730-6	3.3	35
168	A Portuguese value set for the SF-6D. Value in Health, 2010 , 13, 624-30	3.3	35
167	Estimating a preference-based index for a menopause specific health quality of life questionnaire. Health and Quality of Life Outcomes, 2005 , 3, 13	3	35
166	Quantifying patient preferences for out-of-hours primary care. <i>Journal of Health Services Research and Policy</i> , 2000 , 5, 214-8	2.4	35
165	The Short-Form 36 (SF-36) Health Survey and its use in pharmacoeconomic evaluation. <i>Pharmacoeconomics</i> , 1995 , 7, 403-15	4.4	35
164	The SF-36 health survey questionnairea tool for economists. <i>Health Economics (United Kingdom)</i> , 1993 , 2, 213-5	2.4	35
163	An Updated Systematic Review of Studies Mapping (or Cross-Walking) Measures of Health-Related Quality of Life to Generic Preference-Based Measures to Generate Utility Values. <i>Applied Health Economics and Health Policy</i> , 2019 , 17, 295-313	3.4	34

(2013-2014)

162	Development of a preference-based index from the National Eye Institute Visual Function Questionnaire-25. <i>JAMA Ophthalmology</i> , 2014 , 132, 310-8	3.9	34
161	Improving the measurement of QALYs in dementia: developing patient- and carer-reported health state classification systems using Rasch analysis. <i>Value in Health</i> , 2012 , 15, 323-33	3.3	33
160	In or out? Income losses in health state valuations: a review. Value in Health, 2010, 13, 298-305	3.3	33
159	How bad is depression? Preference score estimates from depressed patients and the general population. <i>Health Services Research</i> , 2009 , 44, 1406-23	3.4	33
158	Use of visual analog scales in economic evaluation. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2003 , 3, 293-302	2.2	33
157	Rasch analysis in the development of a simplified version of the National Eye Institute Visual-Function Questionnaire-25 for utility estimation. <i>Quality of Life Research</i> , 2012 , 21, 323-34	3.7	32
156	Developing preference-based health measures: using Rasch analysis to generate health state values. <i>Quality of Life Research</i> , 2010 , 19, 907-17	3.7	32
155	Modelling covariates for the SF-6D standard gamble health state preference data using a nonparametric Bayesian method. <i>Social Science and Medicine</i> , 2007 , 64, 1242-52	5.1	32
154	It's all in the name, or is it? The impact of labeling on health state values. <i>Medical Decision Making</i> , 2012 , 32, 31-40	2.5	31
153	Is Meta-Analysis for Utility Values Appropriate Given the Potential Impact Different Elicitation Methods Have on Values?. <i>Pharmacoeconomics</i> , 2015 , 33, 1101-5	4.4	28
152	Mapping Functions in Health-Related Quality of Life: Mapping from Two Cancer-Specific Health-Related Quality-of-Life Instruments to EQ-5D-3L. <i>Medical Decision Making</i> , 2015 , 35, 912-26	2.5	28
151	Quality of life and illness costs in irritable bowel syndrome. <i>Digestion</i> , 2004 , 69, 254-61	3.6	28
150	Comparison of health state utility values derived using time trade-off, rank and discrete choice data anchored on the full health-dead scale. <i>European Journal of Health Economics</i> , 2012 , 13, 575-87	3.6	27
149	Future Directions in Valuing Benefits for Estimating QALYs: Is Time Up for the EQ-5D?. <i>Value in Health</i> , 2019 , 22, 62-68	3.3	26
148	Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L. <i>Quality of Life Research</i> , 2017 , 26, 1163-1176	3.7	24
147	Valuing Child Health Utility 9D Health States with Young Adults: Insights from a Time Trade Off Study. <i>Applied Health Economics and Health Policy</i> , 2015 , 13, 485-92	3.4	24
146	An assessment of validity and responsiveness of generic measures of health-related quality of life in hearing impairment. <i>Quality of Life Research</i> , 2013 , 22, 2813-28	3.7	24
145	Exploring the consistency of the SF-6D. <i>Value in Health</i> , 2013 , 16, 1023-31	3.3	24

144	What value health?: A review of health state values used in early technology assessments for NICE. <i>Applied Health Economics and Health Policy</i> , 2005 , 4, 219-28	3.4	24
143	Estimating utilities from individual health preference data: a nonparametric Bayesian method. Journal of the Royal Statistical Society Series C: Applied Statistics, 2005, 54, 879-895	1.5	24
142	The cost and effectiveness of the London Helicopter Emergency Medical Service. <i>Journal of Health Services Research and Policy</i> , 1996 , 1, 232-7	2.4	23
141	The Identification, Review and Synthesis of Health State Utility Values from the Literature. <i>Pharmacoeconomics</i> , 2017 , 35, 43-55	4.4	22
140	Comparison of general population, patient, and carer utility values for dementia health states. <i>Medical Decision Making</i> , 2015 , 35, 68-80	2.5	22
139	Valuing the SF-6Dv2 Classification System in the United Kingdom Using a Discrete-choice Experiment With Duration. <i>Medical Care</i> , 2020 , 58, 566-573	3.1	22
138	3L, 5L, What the L? A NICE Conundrum. Pharmacoeconomics, 2018, 36, 637-640	4.4	22
137	Experience-based utility and own health state valuation for a health state classification system: why and how to do it. <i>European Journal of Health Economics</i> , 2018 , 19, 881-891	3.6	22
136	Estimating a preference-based index from the Clinical Outcomes in Routine Evaluation-Outcome Measure (CORE-OM): valuation of CORE-6D. <i>Medical Decision Making</i> , 2013 , 33, 381-95	2.5	22
135	A comparison of United States and United Kingdom EQ-5D health states valuations using a nonparametric Bayesian method. <i>Statistics in Medicine</i> , 2010 , 29, 1622-34	2.3	22
134	School nursing: costs and potential benefits. <i>Journal of Advanced Nursing</i> , 2000 , 31, 1063-71	3.1	22
133	Deriving a Preference-Based Measure for Myelofibrosis from the EORTC QLQ-C30 and the MF-SAF. <i>Value in Health</i> , 2015 , 18, 846-55	3.3	21
132	Developing a New Version of the SF-6D Health State Classification System From the SF-36v2: SF-6Dv2. <i>Medical Care</i> , 2020 , 58, 557-565	3.1	21
131	Utility scores for the Health Utilities Index Mark 2: an empirical assessment of alternative mapping functions. <i>Medical Care</i> , 2005 , 43, 627-35	3.1	21
130	The Capability Approach: A Critical Review of Its Application in Health Economics. <i>Value in Health</i> , 2016 , 19, 795-799	3.3	21
129	Development of the multi-attribute Adolescent Health Utility Measure (AHUM). <i>Health and Quality of Life Outcomes</i> , 2012 , 10, 102	3	20
128	Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods. <i>Medical Care</i> , 2012 , 50, 452-9	3.1	20
127	Comparison of Modes of Administration and Alternative Formats for Eliciting Societal Preferences for Burden of Illness. <i>Applied Health Economics and Health Policy</i> , 2016 , 14, 89-104	3.4	19

(2015-2017)

126	Comparing Generic and Condition-Specific Preference-Based Measures in Epilepsy: EQ-5D-3L and NEWQOL-6D. <i>Value in Health</i> , 2017 , 20, 687-693	3.3	19
125	Health state utilities for skeletal-related events secondary to bone metastases. <i>European Journal of Health Economics</i> , 2014 , 15, 7-18	3.6	19
124	Impact of intravenous drug use on quality of life for patients with venous ulcers. <i>Journal of Advanced Nursing</i> , 2007 , 58, 458-67	3.1	19
123	Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women. <i>Journal of the Operational Research Society</i> , 2005 , 56, 214-221	2	19
122	U.K. utility weights for the EORTC QLU-C10D. Health Economics (United Kingdom), 2019, 28, 1385-1401	2.4	18
121	Mapping from disease-specific to generic health-related quality-of-life scales: a common factor model. <i>Value in Health</i> , 2013 , 16, 177-84	3.3	18
120	Comparison of contemporaneous EQ-5D and SF-6D responses using scoring algorithms derived from similar valuation exercises. <i>Value in Health</i> , 2014 , 17, 570-7	3.3	18
119	Monitoring outcomes for the Medicare Advantage program: methods and application of the VR-12 for evaluation of plans. <i>Journal of Ambulatory Care Management</i> , 2012 , 35, 263-276	0.8	18
118	A comparison of patient and population values for health states in varicose veins patients. <i>Health Economics (United Kingdom)</i> , 2007 , 16, 395-405	2.4	18
117	Health state utility values: a description of their development and application for rheumatic diseases. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1018-26		18
116	Multi-attribute utility function or statistical inference models: a comparison of health state valuation models using the HUI2 health state classification system. <i>Journal of Health Economics</i> , 2007 , 26, 992-1002	3.5	18
115	A review of quality of life themes in Duchenne muscular dystrophy for patients and carers. <i>Health and Quality of Life Outcomes</i> , 2018 , 16, 237	3	18
114	Consistency Between Three Different Ways of Administering the Short Form 6 Dimension Version 2. <i>Value in Health</i> , 2019 , 22, 837-842	3.3	17
113	Valuing states from multiple measures on the same visual analogue sale: a feasibility study. <i>Health Economics (United Kingdom)</i> , 2012 , 21, 715-29	2.4	17
112	Does the EQ-5D reflect lost earnings?. <i>Pharmacoeconomics</i> , 2012 , 30, 47-61	4.4	17
111	Understanding the effect of disease adaptation information on general population values for hypothetical health states. <i>Social Science and Medicine</i> , 2011 , 72, 1904-12	5.1	17
110	The use of QALY and non-QALY measures of health-related quality of life. Assessing the state of the art. <i>Pharmacoeconomics</i> , 1998 , 13, 411-20	4.4	17
109	Developing a utility index for the Aberrant Behavior Checklist (ABC-C) for fragile X syndrome. <i>Quality of Life Research</i> , 2015 , 24, 305-14	3.7	16

108	Lifestyle Matters for maintenance of health and wellbeing in people aged 65 years and over: study protocol for a randomised controlled trial. <i>Trials</i> , 2013 , 14, 302	2.8	16
107	Comparing the measurement equivalence of EQ-5D-5L across different modes of administration. <i>Health and Quality of Life Outcomes</i> , 2015 , 13, 191	3	16
106	Estimating health state utility values for comorbid health conditions using SF-6D data. <i>Value in Health</i> , 2011 , 14, 740-5	3.3	16
105	Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review. <i>BMC Ophthalmology</i> , 2013 , 13, 74	2.3	15
104	Measures of health-related quality of life in an imperfect world: a comment on Dowie. <i>Health Economics (United Kingdom)</i> , 2002 , 11, 17-9; discussion 21-2	2.4	15
103	Health-related quality of life impact of a triple combination of olmesartan medoxomil, amlodipine besylate and hydrochlorotiazide in subjects with hypertension. <i>Health and Quality of Life Outcomes</i> , 2015 , 13, 24	3	14
102	The impact of adding an extra dimension to a preference-based measure. <i>Social Science and Medicine</i> , 2011 , 73, 245-53	5.1	14
101	Estimation of utilities in attention-deficit hyperactivity disorder for economic evaluations. <i>Patient</i> , 2011 , 4, 247-57	3.7	14
100	Using a Discrete-Choice Experiment Involving Cost to Value a Classification System Measuring the Quality-of-Life Impact of Self-Management for Diabetes. <i>Value in Health</i> , 2018 , 21, 69-77	3.3	13
99	A comparison of Hong Kong and United Kingdom SF-6D health states valuations using a nonparametric Bayesian method. <i>Value in Health</i> , 2014 , 17, 397-405	3.3	13
98	Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non-ST-segment elevation acute coronary syndromes. <i>Value in Health</i> , 2011 , 14, 24-33	3.3	13
97	A systematic review of health-related quality of life instruments used for people with venous ulcers: an assessment of their suitability and psychometric properties. <i>Journal of Clinical Nursing</i> , 2010 , 19, 2673-703	3.2	13
96	An application of the SF-6D to create heath values in Portuguese working age adults. <i>Journal of Medical Economics</i> , 2008 , 11, 215-33	2.4	13
95	Public involvement in health outcomes research: lessons learnt from the development of the recovering quality of life (ReQoL) measures. <i>Health and Quality of Life Outcomes</i> , 2019 , 17, 60	3	12
94	Measuring Health-Related Quality of Life in Adolescent Populations: An Empirical Comparison of the CHU9D and the PedsQL 4.0 Short Form 5. Patient, 2018 , 11, 29-37	3.7	12
93	Is the EQ-5D fit for purpose in asthma? Acceptability and content validity from the patient perspective. <i>Health and Quality of Life Outcomes</i> , 2018 , 16, 160	3	12
92	Valuations of epilepsy-specific health states: a comparison of patients with epilepsy and the general population. <i>Epilepsy and Behavior</i> , 2014 , 36, 12-7	3.2	12
91	Measurement of utility values in the UK for health states related to immune thrombocytopenic purpura. <i>Current Medical Research and Opinion</i> , 2010 , 26, 1893-903	2.5	12

(2011-2010)

90	A randomised controlled trial and cost-effectiveness evaluation of "booster" interventions to sustain increases in physical activity in middle-aged adults in deprived urban neighbourhoods. <i>BMC Public Health</i> , 2010 , 10, 3	4.1	12
89	Criteria for item selection for a preference-based measure for use in economic evaluation. <i>Quality of Life Research</i> , 2021 , 30, 1425-1432	3.7	12
88	Patients' with type 2 diabetes willingness to pay for insulin therapy and clinical outcomes. <i>BMJ Open Diabetes Research and Care</i> , 2016 , 4, e000192	4.5	11
87	Integrating Qualitative and Quantitative Data in the Development of Outcome Measures: The Case of the Recovering Quality of Life (ReQoL) Measures in Mental Health Populations. <i>International Journal of Environmental Research and Public Health</i> , 2018 , 15,	4.6	11
86	Healthy year equivalents versus quality-adjusted life years: the debate continues. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005 , 5, 245-54	2.2	11
85	Vignette-Based Utilities: Usefulness, Limitations, and Methodological Recommendations. <i>Value in Health</i> , 2021 , 24, 812-821	3.3	11
84	Estimating a Preference-Based Single Index Measuring the Quality-of-Life Impact of Self-Management for Diabetes. <i>Medical Decision Making</i> , 2018 , 38, 699-707	2.5	11
83	Exploring a new method for deriving the monetary value of a QALY. <i>European Journal of Health Economics</i> , 2016 , 17, 801-9	3.6	10
82	The Use of Health State Utility Values in Decision Models. <i>Pharmacoeconomics</i> , 2017 , 35, 77-88	4.4	10
81	Does the whole equal the sum of the parts? Patient-assigned utility scores for IBS-related health states and profiles. <i>Health Economics (United Kingdom)</i> , 2006 , 15, 543-51	2.4	10
80	Impact of discussion on preferences elicited in a group setting. <i>Health and Quality of Life Outcomes</i> , 2006 , 4, 22	3	10
79	Determining Value in Health Technology Assessment: Stay the Course or Tack Away?. <i>Pharmacoeconomics</i> , 2019 , 37, 293-299	4.4	10
78	Estimating Health State Utility Values for Comorbidities. <i>Pharmacoeconomics</i> , 2017 , 35, 89-94	4.4	9
77	A pragmatic randomised controlled trial assessing the non-inferiority of counselling for depression versus cognitive-behaviour therapy for patients in primary care meeting a diagnosis of moderate or severe depression (PRaCTICED): Study protocol for a randomised controlled trial. <i>Trials</i> , 2017 , 18, 93	2.8	9
76	Is Dimension Order Important when Valuing Health States Using Discrete Choice Experiments Including Duration?. <i>Pharmacoeconomics</i> , 2017 , 35, 439-451	4.4	9
75	How to measure quality of life for cost-effectiveness analyses of personality disorders: a systematic review. <i>Journal of Personality Disorders</i> , 2013 , 27, 383-401	2.6	9
74	Common scale valuations across different preference-based measures: estimation using rank data. <i>Medical Decision Making</i> , 2013 , 33, 839-52	2.5	9
73	Do Portuguese and UK health state values differ across valuation methods?. <i>Quality of Life Research</i> , 2011 , 20, 609-19	3.7	9

72	'Is there a case for using visual analogue scale valuations in CUA' by Parkin and Devlin. A response: 'yes there is a case, but what does it add to ordinal data?'. <i>Health Economics (United Kingdom)</i> , 2007 , 16, 645-7; discussion 649-51	2.4	9
71	A pilot Internet "value of health" panel: recruitment, participation and compliance. <i>Health and Quality of Life Outcomes</i> , 2006 , 4, 90	3	9
70	Estimating an exchange rate between the EQ-5D-3L and ASCOT. <i>European Journal of Health Economics</i> , 2018 , 19, 653-661	3.6	8
69	Modeling SF-6D Hong Kong standard gamble health state preference data using a nonparametric Bayesian method. <i>Value in Health</i> , 2013 , 16, 1032-45	3.3	8
68	Evaluating the Relationship Between Visual Acuity and Utilities in Patients With Diabetic Macular Edema Enrolled in Intravitreal Aflibercept Studies 2017 , 58, 4818-4825		8
67	Identifying and Reviewing Health State Utility Values for Populating Decision Models 2010 , 93-105		8
66	Estimating a Preference-Based Index for Mental Health From the Recovering Quality of Life Measure: Valuation of Recovering Quality of Life Utility Index. <i>Value in Health</i> , 2021 , 24, 281-290	3.3	8
65	Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam. <i>Quality of Life Research</i> , 2017 , 26, 749-759	3.7	7
64	The Simplified Chinese version of SF-6Dv2: translation, cross-cultural adaptation and preliminary psychometric testing. <i>Quality of Life Research</i> , 2020 , 29, 1385-1391	3.7	7
63	Economic evaluation in short bowel syndrome (SBS): an algorithm to estimate utility scores for a patient-reported SBS-specific quality of life scale (SBS-QoL) <i>Quality of Life Research</i> , 2014 , 23, 449-58	3.7	7
62	A comparison of the discriminative and evaluative properties of the SF-36 and the SF-6D index. <i>Quality of Life Research</i> , 2011 , 20, 1477-86	3.7	7
61	The precision of health state valuation by members of the general public using the standard gamble. <i>Quality of Life Research</i> , 2009 , 18, 509-18	3.7	7
60	What is the best approach to adopt for identifying the domains for a new measure of health, social care and carer-related quality of life to measure quality-adjusted life years? Application to the development of the EQ-HWB?. European Journal of Health Economics, 2021, 22, 1067-1081	3.6	7
59	Producing a preference-based quality of life measure for people with Duchenne muscular dystrophy: a mixed-methods study protocol. <i>BMJ Open</i> , 2019 , 9, e023685	3	6
58	Measuring the Burden of Schizophrenia Using Clinician and Patient-Reported Measures: An Exploratory Analysis of Construct Validity. <i>Patient</i> , 2019 , 12, 405-417	3.7	6
57	Mapping From Visual Acuity to EQ-5D, EQ-5D With Vision Bolt-On, and VFQ-UI in Patients With Macular Edema in the LEAVO Trial. <i>Value in Health</i> , 2020 , 23, 928-935	3.3	6
56	Development of a New Quality of Life Measure for Duchenne Muscular Dystrophy Using Mixed Methods: The DMD-QoL. <i>Neurology</i> , 2021 , 96, e2438-e2450	6.5	6
55	Patient-reported prevalence of metamorphopsia and predictors of vision-related quality of life in vitreomacular traction: a prospective, multi-centre study. <i>Eye</i> , 2019 , 33, 435-444	4.4	6

(2014-2017)

54	Recommended Methods for the Collection of Health State Utility Value Evidence in Clinical Studies. <i>Pharmacoeconomics</i> , 2017 , 35, 67-75	4.4	5	
53	Exploring the item sets of the Recovering Quality of Life (ReQoL) measures using factor analysis. <i>Quality of Life Research</i> , 2019 , 28, 1005-1015	3.7	5	
52	Examining the Feasibility and Acceptability of Valuing the Arabic Version of SF-6D in a Lebanese Population. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	5	
51	Measurement and Valuation of Health for Economic Evaluation 2017 , 586-593		5	
50	BENEFITS OF IN-VITRO FERTILISATION. Lancet, The, 1989, 334, 1327-1329	40	5	
49	Selecting Bolt-on Dimensions for the EQ-5D: Testing the Impact of Hearing, Sleep, Cognition, Energy, and Relationships on Preferences Using Pairwise Choices. <i>Medical Decision Making</i> , 2021 , 41, 89-99	2.5	5	
48	What Is the Health and Well-Being Burden for Parents Living With a Child With ADHD in the United Kingdom?. <i>Journal of Attention Disorders</i> , 2021 , 25, 1962-1976	3.7	4	
47	Modeling a preference-based index for two condition-specific measures (asthma and overactive bladder) using a nonparametric Bayesian method. <i>Value in Health</i> , 2014 , 17, 406-15	3.3	4	
46	Examining the incremental impact of long-standing health conditions on subjective well-being alongside the EQ-5D. <i>Health and Quality of Life Outcomes</i> , 2014 , 12, 61	3	4	
45	Clustering Rasch results: a novel method for developing rheumatoid arthritis states for use in valuation studies. <i>Value in Health</i> , 2010 , 13, 787-95	3.3	4	
44	Effect of Reflection and Deliberation on Health State Values: A Mixed-Methods Study. <i>Value in Health</i> , 2019 , 22, 1311-1317	3.3	4	
43	Measurement of Utilities Associated with Parenteral Support Requirement in Patients with Short Bowel Syndrome and Intestinal Failure. <i>Clinical Therapeutics</i> , 2018 , 40, 1878-1893.e1	3.5	4	
42	Valuing child and adolescent health: a qualitative study on different perspectives and priorities taken by the adult general public. <i>Health and Quality of Life Outcomes</i> , 2021 , 19, 222	3	4	
41	Developing a preference-based utility scoring algorithm for the Psoriasis Area Severity Index (PASI). <i>Journal of Medical Economics</i> , 2019 , 22, 936-944	2.4	3	
40	Do Discrete Choice Experiments Approaches Perform Better Than Time Trade-Off in Eliciting Health State Utilities? Evidence From SF-6Dv2 in China. <i>Value in Health</i> , 2020 , 23, 1391-1399	3.3	3	
39	Are Current Reporting Standards Used to Describe Health State Utilities in Cost-Effectiveness Models Satisfactory?. <i>Value in Health</i> , 2020 , 23, 397-405	3.3	3	
38	Deriving health utility values from a randomized, double-blind, placebo-controlled trial of siltuximab in subjects with multicentric Castleman's disease. <i>Current Medical Research and Opinion</i> , 2016 , 32, 1193-200	2.5	3	
37	Predicting preference-based utility values using partial proportional odds models. <i>BMC Research Notes</i> , 2014 , 7, 438	2.3	3	

36	Using mixed methods research to explore the effect of an adaptation exercise on general population valuations of health states. <i>Quality of Life Research</i> , 2012 , 21, 465-73	3.7	3
35	Androgen Deprivation Therapy for Prostate Cancer Prevention: What Impact Do Related Adverse Events Have on Quality of Life?. <i>Health Outcomes Research in Medicine</i> , 2012 , 3, e169-e180		3
34	Assessing current health-related quality of life questionnaires administered to patients with venous ulcers: can they be used in economic evaluations?. <i>Journal of Clinical Nursing</i> , 2010 , 19, 892-7	3.2	3
33	Sample Sizes for the SF-6D Preference Based Measure of Health from the SF-36: A Comparison of Two Methods. <i>Health Services and Outcomes Research Methodology</i> , 2003 , 4, 35-47	1.6	3
32	Improving the validity of economic evaluations alongside controlled trials. <i>Journal of Health Services Research and Policy</i> , 1999 , 4, 161-3	2.4	3
31	Hormone replacement therapy for osteoporosis. <i>Lancet, The</i> , 1990 , 335, 978	40	3
30	The SF-6Dv2: How Does the New Classification System Impact the Distribution of Responses Compared with the Original SF-6D?. <i>Pharmacoeconomics</i> , 2020 , 38, 1283-1288	4.4	3
29	Person-centred experiential therapy versus cognitive behavioural therapy delivered in the English Improving Access to Psychological Therapies service for the treatment of moderate or severe depression (PRaCTICED): a pragmatic, randomised, non-inferiority trial. <i>Lancet Psychiatry,the</i> , 2021 ,	23.3	3
28	Valuation of SF-6Dv2 Health States in China Using Time Trade-off and Discrete-Choice Experiment with a Duration Dimension. <i>Pharmacoeconomics</i> , 2021 , 39, 521-535	4.4	3
27	The EQ Health and Wellbeing: Overview of the Development of a Measure of Health and Wellbeing and Key Results <i>Value in Health</i> , 2022 ,	3.3	3
26	A Qualitative Study of the Views of Health and Social Care Decision-makers on the Role of Wellbeing in Resource Allocation Decisions in the UK. <i>Economies</i> , 2019 , 7, 14	2	2
25	Prevalence of Metamorphopsia in Patients with Vitreomacular Traction, with or without Macular Hole, and its Impact on Quality of Life: The Memo Study. <i>Value in Health</i> , 2016 , 19, A126	3.3	2
24	Health Utility Measurement 2011 , 787-813		2
23	AN ECONOMIC REVIEW OF THE NHS WHITE PAPER. Scottish Journal of Political Economy, 1991 , 38, 96-1	Q5 7	2
22	Qualitative Review on Domains of Quality of Life Important for Patients, Social Care Users, and Informal Carers to Inform the Development of the EQ-HWB <i>Value in Health</i> , 2022 , 25, 492-511	3.3	2
21	Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study. <i>Pharmacoeconomics</i> , 2021 , 39, 913-93	2 4 ·4	2
20	Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists. <i>European Journal of Health Economics</i> , 2021 , 22, 723-733	3.6	2
19	A Comparison of the SF-6Dv2 and SF-6D UK Utility Values in a Mixed Patient and Healthy Population. <i>Pharmacoeconomics</i> , 2021 , 39, 929-940	4.4	2

18	Adapting preference-based utility measures to capture the impact of cancer treatment-related symptoms. <i>European Journal of Health Economics</i> , 2021 , 22, 1301-1309	3.6	2
17	Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT. <i>Health Technology Assessment</i> , 2021 , 25, 1-196	4.4	2
16	Health State Utilities of Patients with Heart Failure: A Systematic Literature Review. <i>Pharmacoeconomics</i> , 2021 , 39, 211-229	4.4	2
15	An item response theory analysis of an item pool for the recovering quality of life (ReQoL) measure. <i>Quality of Life Research</i> , 2021 , 30, 267-276	3.7	2
14	Deriving a Preference-Based Measure for People With Duchenne Muscular Dystrophy From the DMD-QoL. <i>Value in Health</i> , 2021 , 24, 1499-1510	3.3	2
13	Generation, Selection, and Face Validation of Items for a New Generic Measure of Quality of Life: The EQ Health and Wellbeing <i>Value in Health</i> , 2022 ,	3.3	2
12	Developing a New Generic Health and Wellbeing Measure: Psychometric Survey Results for the EQ-HWB <i>Value in Health</i> , 2022 , 25, 525-533	3.3	1
11	Measuring What Matters: Little Evidence Supporting the Content Validity of EQ-5D in People with Duchenne Muscular Dystrophy and Their Caregivers. <i>Medical Decision Making</i> , 2021 , 272989X21106223	7 ^{2.5}	1
10	Modelling a preference-based index for EQ-5D-3L and EQ-5D-3L + Sleep using a Bayesian framework. <i>Quality of Life Research</i> , 2020 , 29, 1495-1507	3.7	1
9	How to measure fluctuating impairments in people with MS: development of an ambulatory assessment version of the EQ-5D-5L in an exploratory study. <i>Quality of Life Research</i> , 2021 , 30, 2081-209) 67	1
8	The Online Elicitation of Personal Utility Functions (OPUF) tool: a new method for valuing health states. <i>Wellcome Open Research</i> ,7, 14	4.8	O
7	Valuing SF-6Dv2 in Australia Using an International Protocol. <i>Pharmacoeconomics</i> , 2021 , 39, 1151-1162	4.4	O
6	Development of the SF-6Dv2 health utility survey: comprehensibility and patient preference Journal of Patient-Reported Outcomes, 2022 , 6, 47	2.6	O
5	Rejoinder to Commentary: When Mapping Treatment Effects from Disease-Specific to Generic Scales, Ordinary Least Squares Regression Underestimates the Benefits of Treatment. <i>Value in Health</i> , 2013 , 16, 217-218	3.3	
4	Response to Comments on Mulhern et al., Improving the Measurement of QALYs in Dementia: Developing Patient- and Carer-Reported Health State Classification Systems Using Rasch Analysis Value in Health, 2012, 15, 787-788	3.3	
3	Response to Shmueli. <i>Health Economics (United Kingdom)</i> , 2007 , 16, 759-761	2.4	
2	Evaluating the "disability paradox" in conjunction with resource allocation. <i>AMA Journal of Ethics</i> , 2005 , 7, 157	1.4	
1	Economic evaluation of complementary therapies 2002 , 199-208		